BioSpace News Archive

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China , today announced its financial results for the fourth quarter and fiscal year of 2020.

Sonnet BioTherapeutics Holdings, Inc. , a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Ascletis Pharma Inc. (HKEX: 1672) announces today that the board of directors (the “Board”) of the Company has resolved to deploy more resources and investment in the R&D of cancer lipid metabolism and oral checkpoint inhibitors, our pipeline of which is shown below:

The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.

Immunovia announced improved performance of its blood based IMMray™ PanCan-d biomarker signature together with CA 19-9, in a clinical retrospective study.

High incidence of post-cataract surgical complications is augmenting the demand for advanced high speed post-surgery correction procedures

The global artificial cornea implant market is likely to expand in the near future. This is mainly because of the increasing cases of corneal eye disease across the globe.

Fact.MR, Rockville MD: An ongoing study on the oral chemotherapy market by consulting firm Fact.MR anticipates a healthy growth outlook for FY 2021-22 and beyond, as global incidence of cancers across key regions increase at an alarming pace.